Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04458688 · ClinicalTrials.gov registry record
Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis
A clinical trial of Multiple Sclerosis (Relapsing Remitting), sponsored by Wayne State University.
- Recruiting
- Registry status
- 80
- Enrollment target
- 1
- Study location
NCT04458688: Recruiting study of Multiple Sclerosis (Relapsing Remitting), sponsored by Wayne State University.
NCT04458688 is a study of Multiple Sclerosis (Relapsing Remitting) that is actively recruiting participants, run by Wayne State University. The registered enrollment target is 80 participants, below the 560-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04458688, a study of Multiple Sclerosis (Relapsing Remitting), is actively recruiting participants, sponsored by Wayne State University.
- RECRUITING
- Registry status
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators intend to examine the effects of ocrelizumab use in African American multiple sclerosis disease course compared to Caucasian disease course utilizing imaging measures with magnetic resonance imaging (MRI) and optical coherence tomography angiography (OCT-A)..
Primary Outcome
Approximately a 1 hour MRI with contrast (administered via IV)
Conditions Studied
Interventions
- OTHER Observation of Ocrelizumab as Treatment in RRMS Patients
Study Locations (1)
Michigan
- Wayne State University - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-11-20 |
| Est. Completion | 2030-12 |
What NCT04458688 shows while recruiting
NCT04458688 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 560-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Multiple Sclerosis (Relapsing Remitting) appearing as the primary indexed condition, and to 1 intervention - of which Observation of Ocrelizumab as Treatment in RRMS Patients is the first listed.
NCT04458688 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT04458688 about?
NCT04458688 is a clinical study titled "Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis". The investigators intend to examine the effects of ocrelizumab use in African American multiple sclerosis disease course compared to Caucasian disease course utilizing imaging measures with magnetic resonance imaging (MRI) and optical coherence tomography angiography (OCT-A)..
What is the current status of trial NCT04458688?
This trial is currently recruiting. The enrollment target is 80 participants. The study started on 2021-11-20. Estimated completion is 2030-12.
What conditions does trial NCT04458688 study?
This clinical trial studies the following conditions: Multiple Sclerosis (Relapsing Remitting).
What interventions are being tested in trial NCT04458688?
The interventions under investigation include: Observation of Ocrelizumab as Treatment in RRMS Patients (OTHER).
Who is sponsoring clinical trial NCT04458688?
This trial is sponsored by Wayne State University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04458688 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis (Relapsing Remitting)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04458688's enrollment target sits among peer trials
80 16th of 29 higher than 14 of 29 other Multiple Sclerosis (Relapsing Remitting) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis (Relapsing Remitting) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis
RECRUITING · NA
-
Intermittent Hypoxia in Persons With Multiple Sclerosis
RECRUITING · NA
-
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
RECRUITING · NA
-
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
RECRUITING · Phase 3
-
MS-ResearchBiomarkerS
RECRUITING
-
Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI